Market openNon-fractional

Viridian Therapeutics/VRDN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Viridian Therapeutics

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.

Ticker

VRDN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Waltham, United States

Employees

94

VRDN Metrics

BasicAdvanced
$782M
Market cap
-
P/E ratio
-$4.41
EPS
1.17
Beta
-
Dividend rate
$782M
1.17
23.991
23.473
3.643
3.769
-104.84%
-29.24%
-46.75%
2,104.449
2.04
2.04
-3.603
-82.59%
-7.59%
-44.37%
-45.76%

What the Analysts think about VRDN

Analyst Ratings

Majority rating from 15 analysts.
Buy

VRDN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$49M
-27.40%
Profit margin
0.00%
NaN%

VRDN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 28.43%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.27
-$1.09
-$1.35
-$0.79
-
Expected
-$1.29
-$1.27
-$1.00
-$1.10
-$0.90
Surprise
-1.89%
-13.91%
34.59%
-28.43%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Viridian Therapeutics stock?

Viridian Therapeutics (VRDN) has a market cap of $782M as of July 05, 2024.

What is the P/E ratio for Viridian Therapeutics stock?

The price to earnings (P/E) ratio for Viridian Therapeutics (VRDN) stock is 0 as of July 05, 2024.

Does Viridian Therapeutics stock pay dividends?

No, Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Viridian Therapeutics dividend payment date?

Viridian Therapeutics (VRDN) stock does not pay dividends to its shareholders.

What is the beta indicator for Viridian Therapeutics?

Viridian Therapeutics (VRDN) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Viridian Therapeutics stock

Buy or sell Viridian Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing